Cargando…

Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice

This systematic review was performed to determine the clinical efficacy and safety of total flavonoids from Rhizoma Drynariae (TFRD) for osteoporotic fractures and to provide clear evidence for clinical practice. Eight databases were searched to identify relevant randomized controlled trials (RCTs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yili, Jiang, Junjie, Shen, Hao, Chai, Yan, Wei, Xu, Xie, Yanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491704/
https://www.ncbi.nlm.nih.gov/pubmed/28694688
http://dx.doi.org/10.2147/DDDT.S139804
_version_ 1783247184270983168
author Zhang, Yili
Jiang, Junjie
Shen, Hao
Chai, Yan
Wei, Xu
Xie, Yanming
author_facet Zhang, Yili
Jiang, Junjie
Shen, Hao
Chai, Yan
Wei, Xu
Xie, Yanming
author_sort Zhang, Yili
collection PubMed
description This systematic review was performed to determine the clinical efficacy and safety of total flavonoids from Rhizoma Drynariae (TFRD) for osteoporotic fractures and to provide clear evidence for clinical practice. Eight databases were searched to identify relevant randomized controlled trials (RCTs) until December 2016. Six RCTs involving 846 patients were included. The primary outcomes included fracture recurrence and death. Meta-analysis showed that both the combination therapy and TFRD alone were better than conventional treatments in improving bone mineral density (BMD) value (weighted mean difference [WMD] =3.68, 95% confidence interval [CI]: 0.01 to 0.04, P=0.0002), (WMD =0.14; 95% CI: 0.11 to 0.16; P<0.00001), respectively, and enhancing therapeutic effect (OR =0.25; 95% CI: 0.12 to 0.51; P=0.0002). Thirty-three patients experienced adverse drug reactions (ADRs), none of the ADRs were severe and all were resolved after symptomatic treatments. Gastrointestinal symptoms were the most common ADRs in the usage of TFRD. Overall, the effect of TFRD on osteoporotic fractures was supported by improving BMD and therapeutic effect. Due to the methodological drawbacks of the included studies, the conclusions should be treated with caution for future research. Registration number: CRD42017052797.
format Online
Article
Text
id pubmed-5491704
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54917042017-07-10 Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice Zhang, Yili Jiang, Junjie Shen, Hao Chai, Yan Wei, Xu Xie, Yanming Drug Des Devel Ther Review This systematic review was performed to determine the clinical efficacy and safety of total flavonoids from Rhizoma Drynariae (TFRD) for osteoporotic fractures and to provide clear evidence for clinical practice. Eight databases were searched to identify relevant randomized controlled trials (RCTs) until December 2016. Six RCTs involving 846 patients were included. The primary outcomes included fracture recurrence and death. Meta-analysis showed that both the combination therapy and TFRD alone were better than conventional treatments in improving bone mineral density (BMD) value (weighted mean difference [WMD] =3.68, 95% confidence interval [CI]: 0.01 to 0.04, P=0.0002), (WMD =0.14; 95% CI: 0.11 to 0.16; P<0.00001), respectively, and enhancing therapeutic effect (OR =0.25; 95% CI: 0.12 to 0.51; P=0.0002). Thirty-three patients experienced adverse drug reactions (ADRs), none of the ADRs were severe and all were resolved after symptomatic treatments. Gastrointestinal symptoms were the most common ADRs in the usage of TFRD. Overall, the effect of TFRD on osteoporotic fractures was supported by improving BMD and therapeutic effect. Due to the methodological drawbacks of the included studies, the conclusions should be treated with caution for future research. Registration number: CRD42017052797. Dove Medical Press 2017-06-23 /pmc/articles/PMC5491704/ /pubmed/28694688 http://dx.doi.org/10.2147/DDDT.S139804 Text en © 2017 Zhang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Zhang, Yili
Jiang, Junjie
Shen, Hao
Chai, Yan
Wei, Xu
Xie, Yanming
Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice
title Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice
title_full Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice
title_fullStr Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice
title_full_unstemmed Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice
title_short Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice
title_sort total flavonoids from rhizoma drynariae (gusuibu) for treating osteoporotic fractures: implication in clinical practice
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491704/
https://www.ncbi.nlm.nih.gov/pubmed/28694688
http://dx.doi.org/10.2147/DDDT.S139804
work_keys_str_mv AT zhangyili totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice
AT jiangjunjie totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice
AT shenhao totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice
AT chaiyan totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice
AT weixu totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice
AT xieyanming totalflavonoidsfromrhizomadrynariaegusuibufortreatingosteoporoticfracturesimplicationinclinicalpractice